Literature DB >> 11369803

Baculovirus-mediated expression and purification of human serum paraoxonase 1A.

R J Brushia1, T M Forte, M N Oda, B N La Du, J K Bielicki.   

Abstract

Human paraoxonase 1 (hPON1) is a lipid-associated enzyme transported on HDL. There is considerable interest in hPON1 because of its putative antioxidative/antiatherogenic properties. We have created a recombinant baculovirus (BV) to generate hPON1A in large quantities for structure-function studies and here describe the method for production and isolation of the enzyme. A high level of recombinant hPON1 type A (rPON1A) was produced by Hi-5 insect cells (40 mg/l); a fraction ( approximately 10 mg/l) was secreted into the cell culture medium, but the majority ( approximately 30 mg/l) remained associated with the host insect cells. Cell-associated rPON1A was purified by detergent extraction (Tergitol NP-10) followed by three simple chromatography steps (DEAE-Sepharose, Sephacryl S-200, and concanavalin A). The purified enzyme bound to concanavalin A and was converted to a lower molecular mass by endoglycosidase H digestion, suggesting that rPON1A contained high-mannose N-glycan chains. There was a significant decrease in arylesterase activity (>99%) concomitant with enzymatic deglycosylation. rPON1A was dependent on Ca(2+) for arylesterase activity, exhibiting kinetic parameters similar to native hPON1A (K(m) = 3.8 +/- 2.1 vs. 3.7 +/- 2.0 mM and V(max) = 1,305 +/- 668 vs. 1,361 +/- 591 U/mg protein, rPON1A and hPON1A, respectively). Both rPON1A and hPON1A efficiently inhibited lipoxygenase-mediated peroxidation of phospholipid. In contrast to the arylesterase activity, which was sensitive to endoglycosidase H treatment, enzymatic deglycosylation did not inhibit the antioxidant activity of rPON1A. In conclusion, our BV-mediated PON1A expression system appears ideally suited for the production of relatively large quantities of rPON1A for structure-function studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369803

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.

Authors:  Amir Aharoni; Leonid Gaidukov; Shai Yagur; Lilly Toker; Israel Silman; Dan S Tawfik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

2.  Engineering human PON1 in an E. coli expression system.

Authors:  Stephanie M Suzuki; Richard C Stevens; Rebecca J Richter; Toby B Cole; Sarah Park; Tamara C Otto; Douglas M Cerasoli; David E Lenz; Clement E Furlong
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 3.  Human paraoxonase 1 as a pharmacologic agent: limitations and perspectives.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  ScientificWorldJournal       Date:  2014-10-20

Review 4.  Paraoxonase 3: Structure and Its Role in Pathophysiology of Coronary Artery Disease.

Authors:  Kumari Priyanka; Surjit Singh; Kirandip Gill
Journal:  Biomolecules       Date:  2019-12-03

5.  A common mutation in paraoxonase-2 results in impaired lactonase activity.

Authors:  David A Stoltz; Egon A Ozer; Thomas J Recker; Miriam Estin; Xia Yang; Diana M Shih; Aldons J Lusis; Joseph Zabner
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

Review 6.  Serum paraoxonase 1 (PON1) measurement: an update.

Authors:  Jose J Ceron; Fernando Tecles; Asta Tvarijonaviciute
Journal:  BMC Vet Res       Date:  2014-03-25       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.